Indrani Kar, PharmD
Large health systems as well as small community hospitals can successfully convert to oncology biosimilars and achieve substantial savings, according to presentations at the ASHP 2020 Midyear Clinical Meeting and Exposition.
University Hospitals (UH) Health System, in northeastern Ohio, achieved approximately $500,000 in savings annually by switching to the biosimilar filgrastim-sndz (Zarxio, Sandoz). Kalispell Regional Medical Center, a 288-bed hospital in